Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in advanced hepatocellular carcinoma
NCT03766776Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of anlotinib in hepatocellular carcinoma (HCC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-Free Survival at 3 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03766776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03766776.